Cityscape: 1L Tiragolumab + Atezolizumab Vs Placebo + Atezolizumab In Pd-L1-Selected Nsclc

CITYSCAPE: 1L tiragolumab + atezolizumab vs placebo + atezolizumab in PD-L1-selected NSCLC

CITYSCAPE: tiragolumab in NSCLC

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

Dr Chitresh Aggarwal | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a 1L

CRSF - Cancer Research and Statistic Foundation

Phase 3 trials of atezolizumab versus standard chemotherapy in PD-L1-selected NSCLC

EMJ

NSCLC highlights at ASCO 2020

FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC

Dr Melissa Johnson: Tiragolumab/Atezolizumab Potential New Treatment Option for NSCLC

Dr Melissa Johnson: Tiragolumab Plus Atezolizumab Improves Objective Response in CITYSCAPE Trial

Adjuvant atezolizumab in NSCLC

Final OS results of IMvigor130: 1L atezolizumab +/- chemotherapy in metastatic urothelial carcinoma

Atezolizumab Versus Other Immunotherapy Options

ASCO Lung Cancer Roundtable - NSCLC - The CITYSCAPE Trial: Anti TIGIT & Immune Checkpoint Inhibitor

GRACE - Global Resource for Advancing Cancer Education

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091

What role does TIGIT inhibition have in treating hepatocellular carcinoma?

BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC

The Emergence of PD-L1 Inhibitors

IASLC Webinar: World Conference on Lung Cancer 2020 Highlights

T-Cell dynamics in response to neoadjuvant atezolizumab in early NSCLC